-
Je něco špatně v tomto záznamu ?
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
P. Baliakas, A. Agathangelidis, A. Hadzidimitriou, LA. Sutton, E. Minga, A. Tsanousa, L. Scarfò, Z. Davis, XJ. Yan, T. Shanafelt, K. Plevova, Y. Sandberg, FJ. Vojdeman, M. Boudjogra, T. Tzenou, M. Chatzouli, CC. Chu, S. Veronese, A. Gardiner, L....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
NT13493
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Free Medical Journals
od 1946 do Před 1 rokem
Freely Accessible Science Journals
od 1946 do Před 1 rokem
Open Access Digital Library
od 1946-01-01
Open Access Digital Library
od 1946-01-01
ROAD: Directory of Open Access Scholarly Resources
- MeSH
- analýza přežití MeSH
- B-lymfocyty účinky léků imunologie patologie MeSH
- čas zasáhnout při rozvinutí nemoci MeSH
- chronická lymfatická leukemie diagnóza farmakoterapie genetika mortalita MeSH
- genetická heterogenita MeSH
- lidé středního věku MeSH
- lidé MeSH
- přestavba genů pro těžké řetězce B-lymfocytů imunologie MeSH
- prognóza MeSH
- protinádorové látky terapeutické užití MeSH
- regulace genové exprese u leukemie * MeSH
- senioři MeSH
- somatická hypermutace imunoglobulinových genů MeSH
- těžké řetězce imunoglobulinů genetika MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
1st Department of Propaedeutic Medicine University of Athens Athens Greece
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Haematology Royal Bournemouth Hospital Bournemouth United Kingdom
Department of Hemato Oncology Belfast City Hospital Belfast United Kingdom
Department of Hematology Rigshospitalet Copenhagen Denmark
Department of Immunology Mayo Clinic Rochester MN
Department of Informatics Aristotle University of Thessaloniki Thessaloniki Greece
Department of Medicine Solna Clinical Epidemiology Unit Karolinska Institutet Stockholm Sweden
Division of Hematology Department of Medicine Mayo Clinic Rochester MN
Hematology Department and University Pierre et Marie Curie Hopital Pitie Salpetriere Paris France
Hematology Department Nikea General Hospital Piraeus Greece
Hôpital Pitié Salpêtrière Service d'Hématologie Biologique Paris France
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Lund University and Hospital Department of Hematology Lund Stem Cell Center Lund Sweden
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15022842
- 003
- CZ-PrNML
- 005
- 20191009131544.0
- 007
- ta
- 008
- 150709s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1182/blood-2014-09-600874 $2 doi
- 035 __
- $a (PubMed)25634617
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Baliakas, Panagiotis $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;
- 245 10
- $a Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations / $c P. Baliakas, A. Agathangelidis, A. Hadzidimitriou, LA. Sutton, E. Minga, A. Tsanousa, L. Scarfò, Z. Davis, XJ. Yan, T. Shanafelt, K. Plevova, Y. Sandberg, FJ. Vojdeman, M. Boudjogra, T. Tzenou, M. Chatzouli, CC. Chu, S. Veronese, A. Gardiner, L. Mansouri, KE. Smedby, LB. Pedersen, D. Moreno, K. Van Lom, V. Giudicelli, HS. Francova, F. Nguyen-Khac, P. Panagiotidis, G. Juliusson, L. Angelis, A. Anagnostopoulos, MP. Lefranc, M. Facco, L. Trentin, M. Catherwood, M. Montillo, CH. Geisler, AW. Langerak, S. Pospisilova, N. Chiorazzi, D. Oscier, DF. Jelinek, N. Darzentas, C. Belessi, F. Davi, P. Ghia, R. Rosenquist, K. Stamatopoulos,
- 520 9_
- $a An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a B-lymfocyty $x účinky léků $x imunologie $x patologie $7 D001402
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a regulace genové exprese u leukemie $7 D015973
- 650 _2
- $a přestavba genů pro těžké řetězce B-lymfocytů $x imunologie $7 D015326
- 650 _2
- $a genetická heterogenita $7 D018740
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a těžké řetězce imunoglobulinů $x genetika $7 D007143
- 650 _2
- $a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $x genetika $x mortalita $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a somatická hypermutace imunoglobulinových genů $7 D027041
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a čas zasáhnout při rozvinutí nemoci $7 D061665
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Agathangelidis, Andreas $u Università Vita-Salute San Raffaele, Milan, Italy; Division of Molecular Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy; $7 gn_A_00002103
- 700 1_
- $a Hadzidimitriou, Anastasia $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Institute of Applied Biosciences, Centre for Research and Technology-Hellas, Thessaloniki, Greece;
- 700 1_
- $a Sutton, Lesley-Ann $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;
- 700 1_
- $a Minga, Eva $u Institute of Applied Biosciences, Centre for Research and Technology-Hellas, Thessaloniki, Greece;
- 700 1_
- $a Tsanousa, Athina $u Department of Informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece;
- 700 1_
- $a Scarfò, Lydia $u Università Vita-Salute San Raffaele, Milan, Italy; Division of Molecular Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy;
- 700 1_
- $a Davis, Zadie $u Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom;
- 700 1_
- $a Yan, Xiao-Jie $u The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY;
- 700 1_
- $a Shanafelt, Tait $u Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;
- 700 1_
- $a Plevová, Karla $u Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic; $7 xx0158852
- 700 1_
- $a Sandberg, Yorick $u Department of Immunology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands;
- 700 1_
- $a Vojdeman, Fie Juhl $u Department of Hematology, Rigshospitalet, Copenhagen, Denmark;
- 700 1_
- $a Boudjogra, Myriam $u Hôpital Pitié-Salpêtrière, Service d'Hématologie Biologique, Paris, France;
- 700 1_
- $a Tzenou, Tatiana $u First Department of Propaedeutic Medicine, University of Athens, Athens, Greece;
- 700 1_
- $a Chatzouli, Maria $u Hematology Department, Nikea General Hospital, Piraeus, Greece;
- 700 1_
- $a Chu, Charles C $u The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY;
- 700 1_
- $a Veronese, Silvio $u Molecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milan, Italy;
- 700 1_
- $a Gardiner, Anne $u Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom;
- 700 1_
- $a Mansouri, Larry $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;
- 700 1_
- $a Smedby, Karin E $u Department of Medicine, Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden;
- 700 1_
- $a Pedersen, Lone Bredo $u Department of Hematology, Rigshospitalet, Copenhagen, Denmark;
- 700 1_
- $a Moreno, Denis $u ImMunoGeneTics (IMGT), Université de Montpellier, Laboratoire d'Informatique Gaspard-Monge, Institut de Génétique Humaine, Montpellier, France;
- 700 1_
- $a Van Lom, Kirsten $u Department of Hematology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands;
- 700 1_
- $a Giudicelli, Véronique $u ImMunoGeneTics (IMGT), Université de Montpellier, Laboratoire d'Informatique Gaspard-Monge, Institut de Génétique Humaine, Montpellier, France;
- 700 1_
- $a Francová, Hana $u Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic; $7 xx0101487
- 700 1_
- $a Nguyen-Khac, Florence $u Hematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France;
- 700 1_
- $a Panagiotidis, Panagiotis $u First Department of Propaedeutic Medicine, University of Athens, Athens, Greece;
- 700 1_
- $a Juliusson, Gunnar $u Lund University and Hospital Department of Hematology, Lund Stem Cell Center, Lund, Sweden;
- 700 1_
- $a Angelis, Lefteris $u Department of Informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece; $7 gn_A_00006906
- 700 1_
- $a Anagnostopoulos, Achilles $u Hematology Department and Hematopoietic Cell Transplantation Unit, Georgios Papanicolaou Hospital, Thessaloniki, Greece; $7 gn_A_00005807
- 700 1_
- $a Lefranc, Marie-Paule $u ImMunoGeneTics (IMGT), Université de Montpellier, Laboratoire d'Informatique Gaspard-Monge, Institut de Génétique Humaine, Montpellier, France;
- 700 1_
- $a Facco, Monica $u Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Italy; Venetian Institute of Molecular Medicine, Padova, Italy;
- 700 1_
- $a Trentin, Livio $u Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Italy; Venetian Institute of Molecular Medicine, Padova, Italy;
- 700 1_
- $a Catherwood, Mark $u Department of Hemato-Oncology, Belfast City Hospital, Belfast, United Kingdom;
- 700 1_
- $a Montillo, Marco $u Molecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milan, Italy;
- 700 1_
- $a Geisler, Christian H $u Department of Hematology, Rigshospitalet, Copenhagen, Denmark;
- 700 1_
- $a Langerak, Anton W $u Department of Immunology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands;
- 700 1_
- $a Pospisilova, Sarka $u Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic;
- 700 1_
- $a Chiorazzi, Nicholas $u The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY;
- 700 1_
- $a Oscier, David $u Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom;
- 700 1_
- $a Jelinek, Diane F $u Department of Immunology, Mayo Clinic, Rochester, MN; and.
- 700 1_
- $a Darzentas, Nikos $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Belessi, Chrysoula $u Hematology Department, Nikea General Hospital, Piraeus, Greece;
- 700 1_
- $a Davi, Frederic $u Hematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France;
- 700 1_
- $a Ghia, Paolo $u Università Vita-Salute San Raffaele, Milan, Italy; Division of Molecular Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy;
- 700 1_
- $a Rosenquist, Richard $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;
- 700 1_
- $a Stamatopoulos, Kostas $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Institute of Applied Biosciences, Centre for Research and Technology-Hellas, Thessaloniki, Greece; Hematology Department and Hematopoietic Cell Transplantation Unit, Georgios Papanicolaou Hospital, Thessaloniki, Greece;
- 773 0_
- $w MED00000807 $t Blood $x 1528-0020 $g Roč. 125, č. 5 (2015), s. 856-859
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25634617 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20191009132002 $b ABA008
- 999 __
- $a ok $b bmc $g 1083181 $s 905835
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 125 $c 5 $d 856-859 $i 1528-0020 $m Blood $n Blood $x MED00000807
- GRA __
- $a NT13493 $p MZ0
- LZP __
- $a Pubmed-20150709
